Clave Capital invests in Leadartis in a funding round of more than €1,600,000


Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its commitment in the field of human health, in this case, together with Sodena and Capital Cell.

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.


Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference

Anglonordic is a great event to meet quality investors and companies - it is very well run and...